MAPT and Alzheimer disease: Similar trends in these biomarkers were observed in late-onset AD (LOAD), where a targeted CSF proteomic panel reflecting diverse brain-based pathophysiology enhanced the ability of Aβ, tau, and pTau in predicting clinical diagnosis, FDG PET, hippocampal volume, and measures of cognitive severity [8].